PromarkerD, the only low cost, high speed test capable of predicting the onset of diabetic kidney disease, exhibited at the Academy of Managed Care Pharmacy Nexus (AMCP Nexus 2021), an in-person conference in Denver, Colorado from the 18th – 21st of October.
The Company presented a PromarkerD clinical utility study as a poster abstract. Poster available here.
Clinical utility study to add to the weight of evidence supporting a US reimbursement code application for PromarkerD.
PromarkerD can predict DKD up to 4 years in advance. A simple test measures 3 plasma biomarkers and 3 clinical factors..
About AMCP Nexus
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.
AMCP advocates at the national and state level for developing and applying evidence-based medication use strategies that improve access to medication, enhance patient and population health outcomes, and safeguard the wise use of health care dollars.